B+
Bull case
15%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
ADCT
ADC TherapeuticsBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
ZYNLONTA monotherapy remains commercially available in 3L+ DLBCL, Q2 net product revenue was $18.6 million, LOTIS-7 enrollment is complete, and management believes the combination with glofitamab could support a leading second-line position. [#SEC-8K-2026-08-13]
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
A strategic reorganization reduced the workforce by approximately 17%, creating execution and organizational-transition risk despite expected cost savings.
Momentum
8
Value
41
Sentiment
83
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.25 · Bull $3.00 · Bear $0.55Analysis 2026-08-18; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $2.63
Why
Momentum8 · Δ7d -
Value41 · Δ7d -0.0
Sentiment83 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • A strategic reorganization reduced the workforce by approximately 17%, creating execution and organizational-transition risk despite expected cost savings.
- • Commercial performance is concentrated in ZYNLONTA monotherapy in 3L+ DLBCL and was described as broadly in line with recent quarters rather than accelerating.
- • The principal value driver, LOTIS-5 full approval, faces explicit FDA benefit-risk concerns.
Catalyst clock
2026-11-16
ASH presentation of LOTIS-5, LOTIS-7, and MZL data
Lead driver: Sentiment · See AI snapshot
Momentum
8
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
83
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 8.1 / Value 41.2 / Sentiment 83.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-18. Scenario method
Most likely
B
Base case
55%
Probability
Target price
$1.25
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.55
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$140.43M
Beta
1.94
Shares Out
127.67M
P/E (TTM) · Derived
-1.0
P/S (TTM)
5.86
P/FCF (TTM) · Derived
-1.55
Rev YoY
+2.2%
EPS YoY
-78.5%
Gross Margin
+88.4%
Op Margin
-121.8%
Net Debt
$178.21M
Current Ratio
3.03
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data